The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Brahmer Expects Rapid Approval for First PD-1 Inhibitor in Lung Cancer
January 25th 2015Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.
Trastuzumab Regimen Lowers Recurrence Risk in Early-Stage, HER2-Positive Breast Cancer
January 20th 2015Results of a phase II study showed that women with small, stage I HER2-positive tumors who received a combination of lower-intensity chemotherapy and the targeted drug trastuzumab following surgery were highly unlikely to have the cancer recur within 3 years.
Expert Discusses Significance of Roche/Foundation Medicine Collaboration
January 15th 2015Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, sat down with OncLive to discuss the recent merger and what that means for the future of precision medicine.
114th Congress Sets Sights on SGR Patch
January 14th 2015With a March 31 deadline looming for the 114th Congress to either patch or repeal the sustainable growth rate (SGR) formula, the Health Subcommittee of the US House of Representatives' Energy and Commerce Committee will hold a hearing to discuss the future of the fundamentally flawed formula used to set Medicare physician payments.
OncLive Welcomes Stephenson Cancer Center to Strategic Alliance Partnership Program
January 12th 2015OncLive® and Stephenson Cancer Center, the only comprehensive academic cancer center in Oklahoma, have become partners in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration
January 9th 2015Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Lanreotide Approval Opens Doors for Treatment of GEP-NETs
January 3rd 2015Lanreotide (Somatuline Depot), which was recently approved by the FDA, is the first and only anti-tumor therapy with a statistically significant progression-free survival benefit in the treatment of adults patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs).
FDA Updates Obinutuzumab Frontline CLL Label
December 25th 2014The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.
Lackluster T-DM1 Results Surprise Perez
December 22nd 2014Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings